Skip to main content
Mural Oncology PLC logo

Mural Oncology PLC — Investor Relations & Filings

Ticker · MURA ISIN · IE000LK2BOB4 BUD Professional, scientific and technical activities
Filings indexed 192 across all filing types
Latest filing 2025-12-05 Director's Dealing
Country IE Ireland
Listing BUD MURA

About Mural Oncology PLC

https://www.muraloncology.com/

Mural Oncology PLC is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer treatment. The company leverages its proprietary protein engineering platform to create novel, cytokine-based therapies. Its primary focus is on developing first- and best-in-class drugs for difficult-to-treat tumor types where other immunotherapies, such as checkpoint inhibitors, have not been effective. The company's pipeline is led by nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy. This candidate is being evaluated in clinical trials for various advanced solid tumors, including platinum-resistant ovarian cancer and advanced melanoma, addressing areas of high unmet medical need.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-12-05 English
Delisting Announcement 2025
Delisting Announcement
2025-12-05 English
8-K
Regulatory Filings
2025-12-05 English
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
M&A Activity Classification · 100% confidence The document is an official announcement regarding the completion of a scheme of arrangement (acquisition) of Mural Oncology plc by XOMA Royalty Corporation. It details the effective date of the acquisition, the cancellation of share trading on Nasdaq, and the process for distributing consideration to shareholders. This falls under M&A activity (takeover/acquisition).
2025-12-05 English
Mural Oncology Announces Sanction of the Scheme by the High Court
M&A Activity Classification · 100% confidence The document is an official announcement regarding the acquisition of Mural Oncology plc by XOMA Royalty Corporation via a scheme of arrangement sanctioned by the High Court of Ireland. It details the effective date of the acquisition, the cancellation of share trading, and the distribution of consideration to shareholders. This falls under M&A activity (takeover bids/mergers).
2025-12-03 English
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
M&A Activity Classification · 100% confidence The document is an announcement regarding the finalization of the 'Additional Price Per Share' in relation to a previously announced acquisition of Mural Oncology plc by XOMA Royalty Corporation. It explicitly references the 'Transaction Agreement' and the 'scheme of arrangement' under the Irish Companies Act. Because this document details the progress and specific financial terms of an ongoing merger/takeover bid, it falls under M&A Activity.
2025-11-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.